Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis

Journal of Rheumatology

Volumn 27, Issue 3, 2000, Pages 601-609

  Moreland, Larry W ^a   McCabe, Dorothy P ^b   Caldwell, Jacques R ^c   Sack, Marshall ^d   Weisman, Michael ^e   Henry, Gregory ^b   Seely, James E ^b   Martin, Steven W ^b   Yee, Clara L ^b   Bendele, Allison M ^b   Frazier, Janet L ^b   Kohno, Tadahiko ^b   Cosenza, Mary Ellen ^b   Lyons, Sheila A ^b   Dayer, Jean Michel ^f   Cohen, Arthur M ^b   Edwards III, Carl K ^b  

^a The University of Alabama at Birmingham   (United States)

^b AMGEN INC   (United States)

^c Florida Arthr and Allergy Institute   (United States)

^d Center for Clinical Research   (United States)

^e UCSD MEDICAL CENTER   (United States)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Rheumatoid arthritis; Treatment; Tumor necrosis factor

Indexed keywords

ANTIBODY; TUMOR NECROSIS FACTOR BINDING PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; IMMUNOGENICITY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINUSITIS; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 0034102538     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
2. Moreland LW, Margolies G, Heck LW Jr, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1993;23:1849-55.
3. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-6.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:259-9.
5. Elliott MG, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
6. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 1993;36:1681-90.
7. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;41:1552-63.
8. Kohno T, Brewer MT, Baker SL, et al. A second tumor necrosis factor gene product can shield a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990;87:8331-5.
9. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease. Arthritis Rheum 1992; 35:1160-9.
10. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990;265:11497-504.
11. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754-9.
12. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Magai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-9.
13. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Differential effect of IL-1 and TNF alpha on the expression of stromelysin, collagenase and the natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix Suppl 1992;1:198-9.
14. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990;8:327-9.
15. Moser RB, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444-55.
16. Chu CQ, Filed M, Feldmann M, Maini RN. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
17. Saxine T, Palladino MA Jr, Heinegard D, Tala N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
18. Deleuran BW, Chu CW, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartliage pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
19. Westacott CI, Atkins RM, Dieppe PA, Elson CJ. Tumor necrosis factor-α receptor expression on chondrocytes isolated from human articular cartilage. J Rheumatol 1994;21:1710-5.
20. Engelmann H, Aderka, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
21. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270-5.
22. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
23. Barrera P, Boerbooms AM, Janssen EM, et al. Circulating soluble tumor necrosis factor receptor, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36:1070-9.
24. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993;13:321-8.
25. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:111-20.
26. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic ostomyelitis and osteoarthritis. Clin Exp Immunol 1993;92:19-22.
27. Zangerle R, Gallati H, Sarcletti M, et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquired Immun Def Synd 1994;7:79-85.
28. Kern P, Hernmer J, Gallati H, et al. Soluble tumor necrosis factor receptors correlate with parisitemia and disease severity in human malaria. J Infect Dis 1992;166:930-4.
29. Furukawa S, Masubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721-5.
30. Andus T, Gross V, Holstege A, et al. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatol 1992;16:749-55.
31. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frendsdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992;42:663-7.
32. Ward RA, Gordon L. Soluble tumor necrosis factor receptors are increased in hemodialysis patients. ASAIO J 1993;39:M782-6.
33. Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M. High levels of circulating soluble receptor for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992;89:1690-3.
34. Elsasser-Beile U, Gallati H, Weber W, Wild ED, Schulte Monting J, von Kleist S. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumour Biol 1994;15:17-24.
35. Froon AH, Bemelmans HM, Greve JW, van der Linden CG, Burrman WA. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome. Correlation with plasma creatinine values. Crit Care Med 1994;22:803-9.
36. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;190:533-6.
37. Kraus T, Mehrabi A, Arnold J, et al. Evaluation of soluble tumor necrosis factor receptors with orthotopic liver transplantation. Transplant Proc 1992;24:2539-41.
38. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurol 1993;43:2679-82.
39. Austgulen R, Liabakk NB, Lien E, Espevik T. Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns. Pediatric Res 1993;33:82-8.
40. Baumann P, Romero R, Berry S, et al. Evidence of participation of the soluble tumor necrosis factor receptor I in the host response to intrauterine infection in preterm labor. Am J Reprod Immunol 1993;30:184-93.
41. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunol 1992;76:20-3.
42. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
43. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
44. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer L, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
45. Hale K, Smith C, Baker S, et al. Multifunctional regulation of the biological effects of TNF-α by the soluble type I and type II TNF receptors. Cytokine 1995;7:26-38.
46. Russell DA, Tucker KK, Chinookoswong N, Thompson RC, Kohno T. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function. J Infect Dis 1995;171:1528-38.
47. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
48. Edwards CK III, Frazier J, Seely J, et al. Assessment of the major antigenic epitodes of the recombinant human soluble p55 TNF Type 1 receptor: design of a novel monomeric non-immunogenic analog, sTNF-RI [abstract]. Arthritis Rheum 1998;Suppl 42:S58.
49. Martin SW, Frazier J, Seely J, el al. A genetically modified tumor necrosis factor receptor I (sTNF-RI) that does not elicit antibody responses in primates [abstract]. Arthritis Rheum 1998;Suppl 42:S58.
50. Pennica D, Lam VT, Mize NK, et al. Biochemical properties of the 75-kDa tumor necrosis factor receptor: characterization of ligand binding, internalization, and receptor phosphyorylation. J Biol Chem 1992;267:21172-8.
51. Tartaglia LA, Weber RF, Figari IS, et al. The two different receptors for tumor necrosis factor mediate distinct cellular response. Proc Natl Acad Sci USA 1991;88:9292-6.
52. Ferrante A, Hauptmann B, Seckinger P, Dayer JM. Inhibition of tumour necrosis factor alpha (TNF-α)-induced neutrophil respiratory burst by a TNF inhibitor. Immunol 1991;72:440-2.
53. Tilg H, Shapiro L, Atkins MB, Dimerallo CA, Mier JW. Induction of circulating and erythrocyte-bound IL-8 and IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 1993;515:3299-307.
54. Cope AP, Gibbons DL, Aderke D, et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of p55 and p75 TNF-R on synovial joint mononuclear cells. Cytokine 1993;5:205-12.
55. Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994;37:232-5.
56. Gatanga T, Hwang CD, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990;87:8781-4.